This new approval allows Mamitra to be marketed in strengths of 150 mg and 440 mg, targeting HER2 overexpressing metastatic breast cancer (MBC), HER2 overexpressing early breast cancer (EBC), and advanced gastric cancer
Read MoreSubscribe to our newsletter to get updates on our latest news